Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis.
OBJECTIVE: Type II collagen (CII) posttranslationally modified by reactive oxygen species (ROS-CII) that are present in the inflamed joint is an autoantigen in rheumatoid arthritis (RA). The aim of this study was to investigate the potential use of anti-ROS-CII autoantibodies as a biomarker of RA. M...
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
2013
|
| _version_ | 1826294747725037568 |
|---|---|
| author | Strollo, R Ponchel, F Malmström, V Rizzo, P Bombardieri, M Wenham, C Landy, R Perret, D Watt, F Corrigall, V Winyard, P Pozzilli, P Conaghan, P Panayi, G Klareskog, L Emery, P Nissim, A |
| author_facet | Strollo, R Ponchel, F Malmström, V Rizzo, P Bombardieri, M Wenham, C Landy, R Perret, D Watt, F Corrigall, V Winyard, P Pozzilli, P Conaghan, P Panayi, G Klareskog, L Emery, P Nissim, A |
| author_sort | Strollo, R |
| collection | OXFORD |
| description | OBJECTIVE: Type II collagen (CII) posttranslationally modified by reactive oxygen species (ROS-CII) that are present in the inflamed joint is an autoantigen in rheumatoid arthritis (RA). The aim of this study was to investigate the potential use of anti-ROS-CII autoantibodies as a biomarker of RA. METHODS: CII was exposed to oxidants that are present in the rheumatoid joint. Autoreactivity to ROS-CII was assessed by enzyme-linked immunosorbent assays in synovial fluid (SF) and serum samples obtained from patients during various phases of RA. This group included disease-modifying antirheumatic drug (DMARD)-naive patients with early RA (n = 85 serum samples) and patients with established RA (n = 80 serum and 50 SF samples), who were categorized as either DMARD responders or DMARD nonresponders. Control subjects included anti-citrullinated protein antibody (ACPA)-positive patients with arthralgia (n = 58 serum samples), patients with osteoarthritis (OA; n = 49 serum and 52 SF samples), and healthy individuals (n = 51 serum samples). RESULTS: Reactivity to ROS-CII among DMARD-naive patients with early RA was significantly higher than that among patients with ACPA-positive arthralgia, patients with OA, and healthy control subjects (P < 0.0001), with 92.9% of serum samples from the patients with early RA binding to anti-ROS-II. There was no significant difference in anti-ROS-CII reactivity between ACPA-positive and ACPA-negative patients with RA, with 93.8% and 91.6% of serum samples, respectively, binding to ROS-CII. The sensitivity and specificity of binding to ROS-CII in patients with early RA were 92% and 98%, respectively. Among patients with established RA, serum reactivity in DMARD nonresponders was significantly higher than that in DMARD responders (P < 0.01); 58.3% of serum samples from nonresponders and 7.6% of serum samples from responders bound to HOCl-ROS, while the respective values for SF were 70% and 60%. In patients with longstanding RA, autoreactivity to ROS-CII changed longitudinally. CONCLUSION: Autoantibodies to ROS-CII have the potential to become diagnostic biomarkers of RA. |
| first_indexed | 2024-03-07T03:50:27Z |
| format | Journal article |
| id | oxford-uuid:c113b9f3-ed88-4646-8c8e-e9c10ad88612 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:50:27Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:c113b9f3-ed88-4646-8c8e-e9c10ad886122022-03-27T05:58:49ZAutoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c113b9f3-ed88-4646-8c8e-e9c10ad88612EnglishSymplectic Elements at Oxford2013Strollo, RPonchel, FMalmström, VRizzo, PBombardieri, MWenham, CLandy, RPerret, DWatt, FCorrigall, VWinyard, PPozzilli, PConaghan, PPanayi, GKlareskog, LEmery, PNissim, AOBJECTIVE: Type II collagen (CII) posttranslationally modified by reactive oxygen species (ROS-CII) that are present in the inflamed joint is an autoantigen in rheumatoid arthritis (RA). The aim of this study was to investigate the potential use of anti-ROS-CII autoantibodies as a biomarker of RA. METHODS: CII was exposed to oxidants that are present in the rheumatoid joint. Autoreactivity to ROS-CII was assessed by enzyme-linked immunosorbent assays in synovial fluid (SF) and serum samples obtained from patients during various phases of RA. This group included disease-modifying antirheumatic drug (DMARD)-naive patients with early RA (n = 85 serum samples) and patients with established RA (n = 80 serum and 50 SF samples), who were categorized as either DMARD responders or DMARD nonresponders. Control subjects included anti-citrullinated protein antibody (ACPA)-positive patients with arthralgia (n = 58 serum samples), patients with osteoarthritis (OA; n = 49 serum and 52 SF samples), and healthy individuals (n = 51 serum samples). RESULTS: Reactivity to ROS-CII among DMARD-naive patients with early RA was significantly higher than that among patients with ACPA-positive arthralgia, patients with OA, and healthy control subjects (P < 0.0001), with 92.9% of serum samples from the patients with early RA binding to anti-ROS-II. There was no significant difference in anti-ROS-CII reactivity between ACPA-positive and ACPA-negative patients with RA, with 93.8% and 91.6% of serum samples, respectively, binding to ROS-CII. The sensitivity and specificity of binding to ROS-CII in patients with early RA were 92% and 98%, respectively. Among patients with established RA, serum reactivity in DMARD nonresponders was significantly higher than that in DMARD responders (P < 0.01); 58.3% of serum samples from nonresponders and 7.6% of serum samples from responders bound to HOCl-ROS, while the respective values for SF were 70% and 60%. In patients with longstanding RA, autoreactivity to ROS-CII changed longitudinally. CONCLUSION: Autoantibodies to ROS-CII have the potential to become diagnostic biomarkers of RA. |
| spellingShingle | Strollo, R Ponchel, F Malmström, V Rizzo, P Bombardieri, M Wenham, C Landy, R Perret, D Watt, F Corrigall, V Winyard, P Pozzilli, P Conaghan, P Panayi, G Klareskog, L Emery, P Nissim, A Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. |
| title | Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. |
| title_full | Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. |
| title_fullStr | Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. |
| title_full_unstemmed | Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. |
| title_short | Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. |
| title_sort | autoantibodies to posttranslationally modified type ii collagen as potential biomarkers for rheumatoid arthritis |
| work_keys_str_mv | AT strollor autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT ponchelf autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT malmstromv autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT rizzop autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT bombardierim autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT wenhamc autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT landyr autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT perretd autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT wattf autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT corrigallv autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT winyardp autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT pozzillip autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT conaghanp autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT panayig autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT klareskogl autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT emeryp autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis AT nissima autoantibodiestoposttranslationallymodifiedtypeiicollagenaspotentialbiomarkersforrheumatoidarthritis |